The cost of bladder tumour treatment and follow-up

被引:34
作者
Hedelin, H [1 ]
Holmäng, S
Wiman, L
机构
[1] Karnsjukhuset, Dept Urol, SE-54185 Skovde, Sweden
[2] Sahlgrens Univ Hosp, Dept Urol, S-41345 Gothenburg, Sweden
来源
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY | 2002年 / 36卷 / 05期
关键词
bladder cancer; cystectomy; cystoscopy; economics; transurethral resection;
D O I
10.1080/003655902320783845
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the costs of bladder tumour treatment and follow-up. Material and Methods: The incidence of bladder tumours, both new and recurrences, and the cost of bladder tumour treatments with curative intent were registered during a 4-year period (1994-97). Results: The incidence of new tumours varied from year to year, in contrast to the number of recurrent tumours, which remained remarkably stable. The total cost of bladder cancer diagnosis, treatment and follow-up was almost 7000 000 SEK per year (2800000 SEK per 100000 inhabitants per year). The number of therapeutic events per year remained stable at 256 +/- 17 (102 per 100000 inhabitants per year). Cystectomies were responsible for 34% of the expenditure and transurethral procedures for 40%. Follow-up cystoscopies accounted for only 13% of the total cost. One-third of the routine follow-up cystoscopies resulted in a therapeutic procedure. The cost of transurethral resections and extirpations was approximately five times higher when performed with the patient hospitalized compared to when performed as day-care surgery. Conclusions: A reduction in the number of follow-up cystoscopies will only produce marginal economic savings. Further savings could be made if more transurethral resections and extirpations/fulgurations were performed on an outpatient basis. Another important goal is to reduce the median cost per cystectomy.
引用
收藏
页码:344 / 347
页数:4
相关论文
共 6 条
[1]   Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence [J].
Boman, H ;
Hedelin, H ;
Holmäng, S .
JOURNAL OF UROLOGY, 2002, 167 (01) :80-83
[2]   Survival after curative treatment of muscle-invasive bladder cancer [J].
Fossa, SD ;
Aass, N ;
Ous, S ;
Waehre, H ;
Ilner, K ;
Hannisdal, E .
ACTA ONCOLOGICA, 1996, 35 :59-65
[3]  
Hedelin H, 1997, Nord Med, V112, P48
[4]  
Neymark N, 1997, EUR UROL, V31, P72
[5]   THE APPLICATION OF A PROGNOSTIC FACTOR-ANALYSIS FOR TA.TL BLADDER-CANCER IN ROUTINE UROLOGICAL PRACTICE [J].
READING, J ;
HALL, RR ;
PARMAR, MKB .
BRITISH JOURNAL OF UROLOGY, 1995, 75 (05) :604-607
[6]   Surveillance for bladder cancer: the management of 4.8 million people [J].
Wright, MPJ ;
Jones, DJ .
BJU INTERNATIONAL, 2000, 85 (04) :431-433